Amedeo A. Azizi
A5044278137- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Neurofibromatosis and Schwannoma Cases
- Meningioma and schwannoma management
- Brain Metastases and Treatment
- Chromatin Remodeling and Cancer
- Vascular Malformations Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Childhood Cancer Survivors' Quality of Life
- Sarcoma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Research Studies
- Radiomics and Machine Learning in Medical Imaging
- Genetic factors in colorectal cancer
- Cerebrospinal fluid and hydrocephalus
- Acute Ischemic Stroke Management
- Neuroendocrine Tumor Research Advances
- Cancer Immunotherapy and Biomarkers
- Renal and related cancers
- Lymphoma Diagnosis and Treatment
- Cerebrovascular and Carotid Artery Diseases
- Cancer Research and Treatments
- Microtubule and mitosis dynamics
- Palliative Care and End-of-Life Issues
Medical University of Vienna
2016-2025
Comprehensive Cancer Center Vienna
2017-2025
Illinois Institute of Technology
2025
Allen Institute for Brain Science
2025
Universitätsklinik für Kinder und Jugendpsychiatrie
2012-2024
University of Vienna
2000-2023
Health and Education Research Management and Epidemiologic Services (United States)
2023
St Anna Children's Hospital
2019-2023
Statistics Austria
2023
University of Hong Kong
2023
Gliomas with histone H3 lysine27-to-methionine mutations (H3K27M-glioma) arise primarily in the midline of central nervous system young children, suggesting a cooperation between genetics and cellular context tumorigenesis. Although H3K27M-glioma are well characterized, their architecture remains uncharted. We performed single-cell RNA sequencing 3321 cells from six primary matched models. found that contain resemble oligodendrocyte precursor (OPC-like), whereas more differentiated malignant...
Abstract Background Pediatric low-grade glioma (pLGG) is essentially a single pathway disease, with most tumors driven by genomic alterations affecting the mitogen-activated protein kinase/ERK (MAPK) pathway, predominantly KIAA1549::BRAF fusions and BRAF V600E mutations. This makes pLGG an ideal candidate for MAPK pathway-targeted treatments. The type I inhibitor, dabrafenib, in combination MEK trametinib, has been approved United States Food Drug Administration systemic treatment of...
Medulloblastoma (MB) is one of the most prevalent forms malignant brain cancer observed within pediatric patients and particularly difficult to diagnose treat due anatomical localization tumors near brainstem. Currently, there are four molecular classifications MBL: WNT, SHH, Group 3, 4 tumor subgroups. Wingless-type (WNT) mutant least common, often caused by mutations in CTNNB1 gene that plays a crucial role wingless cell signaling pathway, yet associates with best prognosis as compared all...
Abstract Background Median survival time of recurrent embryonal brain tumors is short regardless salvage chemotherapy used. An evolving alternative approach to conventional target neovascularization by interfering with tumor angiogenesis at various levels. Procedure From November 2006 December 2010, 16 patients (median age: 9 years) (9 first, 7 multiple) were treated an antiangiogenic multidrug combination regimen (bevacizumab, thalidomide, celecoxib, fenofibrate, etoposide, and...
Abstract Atypical teratoid rhabdoid tumors ( ATRT s) are recently defined highly aggressive embryonal central nervous system with a poor prognosis and no definitive guidelines for treatment. We report on the importance of an initial correct diagnosis disease‐specific therapy outcome in 22 consecutive patients propose new treatment strategy. From 1992 to 2012, nine initially diagnosed correctly as (cohort A, median age 24 months) were treated according intensive multimodal regimen MUV ‐ )...
Purpose Bevacizumab (BEV) is approved in more than 60 countries for use adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) pediatric patients newly diagnosed high-grade glioma (HGG). Methods The randomized, parallel group, multicenter, open-label HERBY trial ( ClinicalTrials.gov identifier: NCT01390948) enrolled age ≥ 3 years ≤ 18 localized, centrally neuropathology-confirmed, nonbrainstem HGG. Eligible were randomly assigned...
PurposeNeurofibromatosis type 1 (NF1) is characterized by a highly variable clinical presentation, but almost all NF1-affected adults present with cutaneous and/or subcutaneous neurofibromas. Exceptions are individuals heterozygous for the NF1 in-frame deletion, c.2970_2972del (p.Met992del), associated mild phenotype without any externally visible tumors.MethodsA total of 135 from 103 unrelated families, carrying constitutional p.Met992del pathogenic variant and clinically assessed using...
Diffuse gliomas with K27M histone mutations (H3K27M glioma) are generally characterized by a fatal prognosis, particularly affecting the pediatric population. Based on molecular heterogeneity observed in this tumor type, personalized treatment is considered to substantially improve therapeutic options. Therefore, clinical evidence for therapy, guided comprehensive profiling, urgently required. In study, we analyzed feasibility and outcomes cohort of 12 H3K27M glioma cases treated at two...
Alterations of the fibroblast growth factor (FGF) signalling pathway are increasingly recognized as frequent oncogenic drivers paediatric brain tumours. We report on three patients treated with selective FGFR1-4 inhibitor erdafitinib. Two were diagnosed a posterior fossa ependymoma group A (PFA EPN) and one low-grade glioma (LGG), harbouring FGFR3/FGFR1 overexpression an FGFR1 internal tandem duplication (ITD), respectively. While both EPN did not respond to erdafitinib treatment,...
The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease patients with neurofibromatosis type 1 (NF1), 2 (NF2), schwannomatosis (SWN), to recommend optimal image acquisition analysis methods enable WB-MRI as endpoint NF clinical trials.A systematic process was used review all published data about syndromes assess diagnostic...
Low grade gliomas (LGGs) constitute the largest, yet clinically and (molecular-) histologically heterogeneous group of pediatric brain tumors WHO grades I II occurring throughout all age groups at central nervous system (CNS) sites. The are characterized by a slow growth rate may show periods arrest. Around 40% LGG patients can be cured complete neurosurgical resection followed close observation. In case relapse, second often is possible. Following incomplete observation recommended, as long...
Medulloblastoma (MB) recurrence is usually incurable despite intensive therapy including high-dose chemotherapy. An evolving alternative approach to conventional chemotherapy aims at interfering with tumor angiogenesis different levels. We report on a novel combinatorial metronomic antiangiogenic approach. The study retrospective observational of 29 consecutive patients first or multiple recurrences prospectively treated according the MEMMAT strategy ("MEMMAT-like") before formal protocol...
Importance Medulloblastoma recurrence in patients who have previously received irradiation has a dismal prognosis and lacks standard salvage regimen. Objective To evaluate the response rate of pediatric with medulloblastoma using an antiangiogenic metronomic combinatorial approach (Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial [MEMMAT]). Design, Setting, Participants This phase 2, investigator-initiated, multicenter nonrandomized controlled trial assessed 40 relapsed...
About 10% of patients with neurofibromatosis type 1 (NF-1) develop malignant peripheral nerve sheath tumours (MPNST) mostly arising in plexiform neurofibroma (PN); 15% MPNST arise children and adolescents. 2-[18 F]fluoro-2-deoxy-d-glucose ([18 F]FDG)-PET (where PET is positron emission tomography) a sensitive method differentiating PN symptomatic NF-1. This study assesses the value [18 F]FDG-PET imaging detecting transformation asymptomatic PN.Forty-one NF-1 extensive underwent prospective...
Constitutional mismatch repair deficiency (CMMRD) is caused by germline pathogenic variants in both alleles of a gene. Patients have an exceptionally high risk numerous pediatric malignancies and benefit from surveillance adjusted treatment. The diversity its manifestation, ambiguous genotyping results, particularly PMS2, can complicate diagnosis preclude timely patient management. Assessment low-level microsatellite instability nonneoplastic tissues detect CMMRD, but current techniques are...
The aim of the project was to identify risk factors associated with visual progression and treatment indications in pediatric patients neurofibromatosis type 1 optic pathway glioma (NF1-OPG).A multidisciplinary expert group consisting ophthalmologists, neuro-oncologists, specialists, neuro-radiologists involved therapy trials assembled a cohort children NF1-OPG from 6 European countries complete clinical, imaging, outcome datasets. Using methods developed during consensus workshop, imaging...
Abstract Background The international, multicenter registry LOGGIC Core BioClinical Data Bank aims to enhance the understanding of tumor biology in pediatric low-grade glioma (pLGG) and provide clinical molecular data support treatment decisions interventional trial participation. Hence, question arises whether implementation RNA sequencing (RNA-Seq) using fresh frozen (FrFr) tissue addition gene panel DNA methylation analysis improves diagnostic accuracy provides additional benefit. Methods...
Abstract Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor group. The natural history, when curative resection not possible, one of a chronic disease with periods stability and episodes progression. While there high overall survival rate, many patients experience significant potentially lifelong morbidities. majority pLGGs have an underlying activation RAS/MAPK pathway due to mutational events, leading use molecularly targeted therapies in clinical trials, recent...
<h3>Objective:</h3> Tumors and other disease complications of neurofibromatosis (NF) can cause pain negatively affect physical functioning. To document the clinical benefit treatment in NF trials targeting these manifestations, patient-reported outcomes (PROs) assessing functioning should be included as study endpoints. Currently, there is no consensus on selection use such measures population. This article presents recommendations PRO group Response Evaluation Neurofibromatosis...